The Luminex Corporation (LMNX) Position Cut by Principal Financial Group Inc.

The Luminex Corporation (LMNX) Position Cut by Principal Financial Group Inc.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Russell Investments Group Ltd. bought a new position in Luminex Corporation during the fourth quarter worth approximately $2,638,000. Comerica Bank increased its position in Luminex Corporation by 5.7% in the fourth quarter. Comerica Bank now owns 42,179 shares of the medical instruments supplier’s stock worth $875,000 after buying an additional 2,293 shares during the period. State Street Corp increased its position in Luminex Corporation by 7.7% in the fourth quarter. State Street Corp now owns 893,438 shares of the medical instruments supplier’s stock worth $18,072,000 after buying an additional 63,926 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Luminex Corporation by 8.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,685,236 shares of the medical instruments supplier’s stock worth $34,093,000 after buying an additional 138,104 shares during the last quarter. Finally, Guggenheim Capital LLC increased its position in Luminex Corporation by 27.1% in the fourth quarter. Guggenheim Capital LLC now owns 73,057 shares of the medical instruments supplier’s stock worth $1,478,000 after buying an additional 15,566 shares during the last quarter. Hedge funds and other institutional investors own 74.15% of the company’s stock.

Principal Financial Group Inc. cut its stake in shares of Luminex Corporation (NASDAQ:LMNX) by 2.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 294,792 shares of the medical instruments supplier’s stock after selling 7,649 shares during the period. Principal Financial Group Inc. owned approximately 0.72% of Luminex Corporation worth $5,415,000 as of its most recent SEC filing.

Shares of Luminex Corporation (NASDAQ LMNX) traded down 0.10% during trading on Wednesday, reaching $20.20. 137,235 shares of the company were exchanged. Luminex Corporation has a one year low of $17.64 and a one year high of $23.62. The stock has a market capitalization of $887.31 million, a price-to-earnings ratio of 62.73 and a beta of 0.29. The company has a 50 day moving average price of $20.77 and a 200-day moving average price of $19.64.

Luminex Corporation (NASDAQ:LMNX) last released its quarterly earnings data on Monday, May 1st. The medical instruments supplier reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.12. Luminex Corporation had a return on equity of 5.48% and a net margin of 5.00%. The business had revenue of $77.80 million during the quarter, compared to analysts’ expectations of $74.25 million. During the same quarter last year, the business posted $0.29 EPS. The business’s revenue was up 23.5% on a year-over-year basis. Equities analysts predict that Luminex Corporation will post $0.52 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, July 14th. Stockholders of record on Friday, June 23rd were given a $0.06 dividend. This represents a $0.24 annualized dividend and a dividend yield of 1.19%. The ex-dividend date was Wednesday, June 21st. Luminex Corporation’s dividend payout ratio is currently 75.00%.

A number of analysts recently weighed in on the stock. ValuEngine raised shares of Luminex Corporation from a “sell” rating to a “hold” rating in a research note on Thursday, May 11th. Zacks Investment Research cut shares of Luminex Corporation from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $21.00 price objective on shares of Luminex Corporation in a research note on Friday, June 9th. BidaskClub cut shares of Luminex Corporation from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Finally, TheStreet upgraded shares of Luminex Corporation from a “c+” rating to a “b-” rating in a report on Friday, May 19th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $21.67.

In other Luminex Corporation news, Director G Walter Loewenbaum II sold 25,000 shares of Luminex Corporation stock in a transaction on Tuesday, May 30th. The stock was sold at an average price of $20.07, for a total value of $501,750.00. Following the completion of the sale, the director now owns 713,896 shares of the company’s stock, valued at approximately $14,327,892.72. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 75,000 shares of company stock valued at $1,527,500 in the last three months. Corporate insiders own 6.90% of the company’s stock.

Luminex Corporation Company Profile

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Related posts

Leave a Comment